Israel’s OrSense, a developer of monitors for non-invasive measurements of various blood parameters, announced successful clinical trial results for anemia screening and hemorrhage detection via non-invasive methods. Dr. Eran Hadar, of the Department of Maternal Fetal Medicine at Rabin Medical Center, said OrSenes’s NBM200 device was as accurate as invasive point of care devices in measuring hemoglobin levels in pregnant women.
“The clinical trial shows that OrSense’s system is accurate and user friendly for determining Hb levels non-invasively,” said Professor Moshe Hod, director of the Maternal Fetal Division of the Women’s Hospital at Rabin Medical Center. “Pregnant women are a particularly vulnerable anemia risk group that will greatly benefit from the ability offered by OrSenes’s solution to immediately and routinely screen for anemia, as part of a regular physician checkup.”
Over one billion people suffer from iron deficiency anemia worldwide. During pregnancy the need for iron increases and exposes the mother to a higher risk of anemia. It is estimated that 40 percent of maternal deaths are caused directly or indirectly by anemia.
The company recently completed an $18 million financing round.
“We believe that this additional investment will help us establish OrSense as the world leader in non-invasive monitoring of various blood parameters, promising a significant improvement to the quality of life of millions of people worldwide,” said OrSense CEO Lior Ma’ayan.
OrSense’s CE approved non-invasive hemoglobin monitor is available in 40 countries worldwide, and has been successfully installed in multiple environments including hospitals, physician offices, blood donation facilities, as well as used for various applications including public screening, women health and homecare.